Global Ganja Report

On New Year’s Day, as retail sales of cannabis went legal in Colorado, the state's dispensaries registered well over $1 million in sales. Despite cold and wet weather, most of the 36 shops that opened that day reported long lines, with some customers waiting outdoors for hours. By the end of the first week, by which time another dozen retail outlets had opened, the figure was a whopping $5 million. More than 100 dispensaries in the Centennial State have now received licenses for retail cannabis sales and over 500 are eligible to apply. More are applying every day.

"A new industry is developing in a nascent state in Colorado," says Rachel Gillette, director of the Colorado chapter of the National Organization for the Reform of Marijuana Laws (NORML). "We're not just talking about retail sales, but a lot of other types of business associated with it—construction companies, HVAC contractors, nutrient companies, lighting and equipment sales, packaging, printers, labeling, marketing materials, websites, marijuana tourism, attorneys, payroll companies… This could represent a lot of jobs."

The US District Court for the Eastern District of California will hold rare formal hearings beginning Oct. 27 to determine whether an indictment against Brian Justin Pickard and others for conspiracy to grow more than 1,000 marijuana plants violates the US Constitution, and whether marijuana is misclassified by the federal government as a dangerous drug with no medical value. US District Judge Kimberly J. Mueller will preside over the three-day hearing, which includes expert testimony from doctors Carl Hart, associate professor of psychology at Columbia University in New York; Greg Carter, medical director of St. Luke's Rehabilitation Institute in Spokane, Wash., and expert witness Chris Conrad.

Dean Becker, a former reporter at non-commercial KPFT in Houston, has produced a worthwhile if deceptively named book in To End the War on Drugs: A Guide for Politicians, the Press and Public. Rather than the activist how-to manual promised in the subtitle, it is a series of interviews with leading lights in the drug policy reform movement. And rather than explaining how, they are mostly making the case as to why the "drug war" must end.

Italy's government announced Sept. 18 plans to cultivate medical marijuana at a secure military lab outside Florence and distribute it through pharmacies. Medical marijuana has been legal in Italy since 2007, but only some 60 patients have signed up with the program overseen by the national healthcare system, the Azienda Sanitaria Locale. The Florence Military Chemical-Pharmaceutical Plant (SCFM) currently produces so-called "orphan drugs" no longer made by large pharmaceutical companies but still needed to treat rare diseases. It is now to grow cannabis under a deal signed between Defense Minister Roberta Pinotti and Health Minister Beatrice Lorenzin. "The institute already produces some medicines," Pinotti told Reuters, addressing the unlikely prospect of entrusting the military with weed cultivation. "And we can guarantee security conditions."

US Rep. Scott Perry (R-PA) on July 29 introduced a bill to legalize cannabidiol (CBD) oil on a national level, citing its effectiveness in treating seizures in children suffering from epilepsy. The "Charlotte's Web Medical Hemp Act of 2014" would remove CBD oil and "therapeutic hemp" from the federal definition of marijuana in the Controlled Substances Act. "Therapeutic hemp" is cannabis that contains no more than .3% THC and therefore produces no "high." Perry announced the bill at press conference where he was joined by the president of the national Epilepsy Foundation and advocates that included the mother of Colorado girl Charlotte Figi, whose successful treatment with  CBD  oil won national interest. Also present was Joel Stanley, one of the creators of the "Charlotte's Web" strain of marijuana used to treat Figi. Introduction of the legislation coincides with a pledge by Pennsylvania's Gov. Tom Corbett to create a state-level pilot program for families whose children require access to medical marijuana. (Jurist, July 29; PennLive, MSBC, July 28)

The American Herbal Products Association (AHPA) released its long-awaited medical marijuana manufacturing guidelines July 22, completing its compendium of industry standards which include regulatory recommendations for cannabis from seed to sale. The AHPA manufacturing guidelines come as licensed Colorado business At Home Baked sees the country's first medical marijuana product recall. A new nationwide program called Patient Focused Certification (PFC), a project of Americans for Safe Access (ASA), aims to bring greater standardization to the medical marijuana industry. The PFC program uses the recently completed AHPA guidelines in combination with standards set by American Herbal Pharmacopoeia (AHP) for the plant's identity, purity, quality and botanical properties. Together, these standards have the means to bring greater accountability to the industry and increased safety for patients.

Los Angeles' first-ever marijuana farmers market was ordered closed by an LA Superior Court judge July 15 after City Attorney Mike Feuer asked for a restraining order against the California Heritage Market. Over the weekend of July 4, the California Heritage Market, a marijuana collective, or dispensary as it is known to the "compassionate care" crowd, opened a warehouse for cannabis cultivators to peddle their products in an open-air atmosphere. Thousands waited for hours to wade through thick crowds looking for bargains among the 60 or so booths selling dried marijuana flowers, hash, oils, and creams. One bubbly vendor told the cameras that he "couldn't believe how high the demand was."

Gov. Andrew Cuomo signed a bill into law July 7 that makes New York the 23rd medical marijuana state. Advocates celebrated a deal struck last month between Cuomo and the state legislature that will protect qualified patients from arrest, prosecution and discrimination, and license up to 20 distribution facilities across the state. The new law empowers the New York State Department of Health (DOH) to license physicians to recommend marijuana to patients with cancer, HIV/AIDS, epilepsy, and a limited range of other medical conditions. However, the law only allows for products that use an extracted form of cannabis, such as oil or edibles, which are to be produced under a state-licensed manufacturing process. Advocates have voiced concerns over the law's 7% tax, and a prohibition on access to whole-plant cannabis. Advocates also raise concerns over the prohibitive cost for many patients who cannot afford to purchase what would otherwise be an inexpensive medicine to grow. The new law gives the DOH 18 months to establish regulations and will sunset in seven years. (ASA, July 7)